Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) (VENUS-2)

This study has been completed.
Boehringer Ingelheim
Information provided by (Responsible Party):
Aktion Bronchialkarzinom e.V. Identifier:
First received: August 28, 2012
Last updated: January 22, 2015
Last verified: January 2015
To investigate the maximum tolerated dose of BIBF 1120 and safety in escalating doses administered with Vinorelbine i.v. and Carboplatin i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: BIBF 1120
Drug: Vinorelbine
Drug: Carboplatin
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV

Resource links provided by NLM:

Further study details as provided by Aktion Bronchialkarzinom e.V.:

Primary Outcome Measures:
  • To investigate the maximum tolerated dose of BIBF 1120 [ Time Frame: Cycle 1 day 1, day 8, day 15; Cycle 2 day 1, day 8, day 15; Cycle 3 day 1, day 8, day 15; Cycle 4 day 1, day 8, day 15; day 84 ]

Secondary Outcome Measures:
  • Incidence of adverse events [ Time Frame: Cycle 1 day 1, day 8, day 15; Cycle 2 day 1, day 8, day 15; Cycle 3 day 1, day 8, day 15; Cycle 4 day 1, day 8, day 15; day 84 ]
  • Response Rate [ Time Frame: Day 43 (prior start of cycle 3), day 84 ]

Enrollment: 8
Study Start Date: April 2013
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIBF 1120, Vinorelbine, Carboplatin

To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.

Under certain conditions the dose level will be escalated to 200mg bid in a second cohort.

Drug: BIBF 1120
2 x 150 mg capsules, oral, daily (Start dose)
Drug: Vinorelbine
25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
Drug: Carboplatin
AUC 5 i.v. on day 1 (three-week cycle)

Detailed Description:

Patients older than 70 years could be enrolled in this clinical trial. The trial is being carried out in two trial centres in Germany.

For the planned sample size it is assumed that two different dosage groups are needed with 6 patients on each dosage group with the option to deescalate the first dosage. Altogether this leads to an estimated sample size of maximal 18 patients.

  • Duration of treatment/patient: up to 6 month
  • Follow Up: at least 6 month

Ages Eligible for Study:   71 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological confirmed Non-Small-Cell lung cancer (NSCLC)
  • Tumor stage IV (UICC 7th Version)
  • ECOG <2
  • Age > 70 years
  • No previous chemotherapy for stage IV NSCLC (UICC 7th Version)
  • Adjuvant or neoadjuvant chemotherapy for NSCLC must be completed at least one year prior to study enrolment (from end of chemotherapy)
  • Patients with prior radiation therapy may be eligible for this study if they meet the following guidelines:

    • Previous radiation therapy is allowed to <25% of the bone marrow (Cristy and Eckerman 1987), but should have been limited and must not have included whole pelvis radiation.
    • Patients must have recovered from the toxic effects of the treatment prior to study enrolment (except for alopecia).
    • Prior thoracic radiotherapy must be completed 30 days before study enrolment.
    • Lesions that have been irradiated cannot be included as sites of measurable disease unless clear tumour progression has been documented in these lesions since the end of radiation therapy.
    • Palliative extrathoracic radiotherapy to pre-existing lesions may continue on study; however, these lesions may not be included as sites of measurable disease.
  • Adequate haematological laboratory parameters:

    • Haemoglobin ≥9 g/dl
    • WBC ≥3.000/µl
    • Platelets ≥ 100.000/µl
    • Neutrophil count > 1,500/µl
  • Adequate renal laboratory parameters

    • Creatinine ≤1,9 mg/dl
    • Creatinine Clearance > 45 ml/min
  • Adequate hepatic function

    • Total bilirubin within normal range
    • Total bilirubin < 1.5 x ULN (patients with liver metastasis)
    • ALT < 1.5 x ULN
    • ALT < 2.5 x ULN (patients with liver metastasis)
    • AST < 1.5 x ULN
    • AST < 2.5 x ULN (patients with liver metastasis)
    • Alk. phosphatase < 3 x ULN
    • LDH < 5 x ULN ULN = Upper Limit Of Normal (ULN)
  • Other lab parameters:

    • Proteinuria < CTCAE grade 2
    • Prothrombin time and/or partial thromboplastin time < 50 % deviation from normal limits
  • Informed consent, personally signed and dated to participate in the study
  • Male patients enrolled in this trial must use adequate barrier birth control measures during the course of treatment and for at least 3 months after the last administration of study therapy
  • Life expectancy at least 3 months

Exclusion Criteria:

  • Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol
  • Serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial, antifungal) therapy
  • Serious, non-healing wound, ulcer or bone fracture or major injuries and/or surgery within 4 weeks of trial inclusion, or planned surgical procedures during the trial period.
  • Investigational drug therapy outside of this trial during or within 4 weeks of study entry
  • Known hypersensitivity to the trial drugs or their excipients.
  • History of other malignancies in the last 5 years, in particular those which could affect compliance with the protocol or interpretation of results. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
  • Serious concomitant disease, especially those that would limit compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
  • Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure >NYHA II)
  • Known inherited predisposition to bleeds or to thrombosis.
  • Patient with brain metastases that are symptomatic and/or require therapy.
  • Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid ≤ 325mg per day)
  • History of major thrombotic events or clinically relevant major bleeding event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis below the joint space of the knee)
  • Current peripheral neuropathy ≥ CTCAE grade 2 except due to trauma
  • Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
  • Active alcohol or drug abuse.
  • Men who are sexually active and unwilling to use a medically acceptable method of contraception
  • Leptomeningeal disease
  • Radiographic evidence of cavitary or necrotic tumours
  • Centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01683682

Krankenhaus Großhansdorf
Großhansdorf, Germany, D-22927
Klinikum Kassel GmbH
Kassel, Germany, D-34125
Sponsors and Collaborators
Aktion Bronchialkarzinom e.V.
Boehringer Ingelheim
Principal Investigator: Prof. Dr. Martin Wolf, MD Klinikum Kassel GmbH, D-34125 Kassel
Study Chair: Prof. Dr. Rudolf M. Huber, MD Klinikum der Universität München, D-80336 München
  More Information

Responsible Party: Aktion Bronchialkarzinom e.V. Identifier: NCT01683682     History of Changes
Other Study ID Numbers: ABC-2011-NSCLC-04
2011-002141-36 ( EudraCT Number )
Study First Received: August 28, 2012
Last Updated: January 22, 2015

Keywords provided by Aktion Bronchialkarzinom e.V.:
Non-Small Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors processed this record on April 21, 2017